Release issued 12th September 2007

September 12, 2007, Waltham, Mass.  Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the patent expiries of Merck's Proscar, Boehringer Ingelheim's Flomax, and Astellas's Omix, combined with the limited emergence of new therapies, will cause a 23% decline in sales of therapies to treat benign Prostatic Hyperplasia over the next five years.

The new Pharmacor report entitled Benign Prostatic Hyperplasia finds that the market to treat the disease is dominated by two drug classes-alpha blockers and 5-alpha-reductase inhibitors-which make up 93% of drug sales in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan. Boehringer Ingelheim's Flomax and Astellas's Omix (both alpha blockers) dominated the market in 2006, comprising half of all benign Prostatic Hyperplasia drug sales. However, the patent expiries of Proscar, Flomax, Omix, and GlaxoSmithKline's Avodart in the United States in 2009 will cause a significant decline in the overall benign Prostatic Hyperplasia market by 2011.

Although patent expiries will constrain the market in the near term, increases in the patient population, unmet need, and higher drug treatment rates from 2011 to 2016 will help create a favorable landscape for novel benign Prostatic Hyperplasia treatments.

"Eli Lilly's Cialis and GlaxoSmithKline's fixed-dose combination of Tamsulosin and Dutasteride, both of which are expected to launch for benign Prostatic Hyperplasia in the United States and in Europe by 2011, are the two most promising agents in the pipeline," said Greg Dwyer, analyst at Decision Resources. "The combined sales of these two drugs will represent nearly 30% of the total benign Prostatic Hyperplasia market in 2016."

About Decision Resources
Decision Resources, Inc. (www.decisionresources.com) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

(23rd December 2008) Novo Nordisk will remain the dominant player in the metabolic drug market in 2014 while Merck will raise its ranking with Januvia

(15th December 2008) Most important factors driving usage of antibiotics in the ICU setting are availability in intravenous formulation, activity against key gram negative pathogens, drug interactions and bactericidal act

(11th December 2008) China’s views on Mental Disorders improving but challenges remain

(10th December 2008) India’s Breast Cancer drug market will almost double by 2012

(9th December 2008) Sales of emerging therapies, most notably Tanezumab and Tapentadol, will nearly double the Chronic Low Back Pain market by 2017